» Articles » PMID: 33419797

Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells

Overview
Journal Anticancer Res
Specialty Oncology
Date 2021 Jan 9
PMID 33419797
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: We have tested whether the anticancer peptide, PNC-27, that kills cancer cells but not normal cells by binding to cancer cell membrane HDM-2 forming pores, kills CD44+ colon cancer stem cells.

Materials And Methods: Flow cytometry determined the CD44 and HDM-2 expression on six-colon cancer cell lines and one normal cell line (CCD-18Co). MTT, LDH release, annexin V binding and caspase 3 assays were used to assess PNC-27-induced cell death. Bioluminescence imaging measured PNC-27 effects on in vivo tumor growth.

Results: High percentages of cells in all six tumor lines expressed CD44. PNC-27 co-localized with membrane HDM-2 only in the cancer cells and caused total cell death (tumor cell necrosis, high LDH release, negative annexin V and caspase 3). In vivo, PNC-27 caused necrosis of tumor nodules but not of normal tissue.

Conclusion: PNC-27 selectively kills colon cancer stem cells by binding of this peptide to membrane H/MDM-2.

Citing Articles

Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.

Pincus M, Silberstein M, Zohar N, Sarafraz-Yazdi E, Bowne W Biomedicines. 2024; 12(6).

PMID: 38927351 PMC: 11201261. DOI: 10.3390/biomedicines12061144.


From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy.

Liu H, Shen W, Liu W, Yang Z, Yin D, Xiao C Bioact Mater. 2023; 31:206-230.

PMID: 37637082 PMC: 10450358. DOI: 10.1016/j.bioactmat.2023.08.007.


P53/MDM2 Complex-Based Targeted Strategies in Colon Adenocarcinoma.

Niotis A, Tsiambas E, Dimitroulis D, Sarlanis H, Falidas E, Kavantzas N Acta Med Acad. 2023; 52(1):24-29.

PMID: 37326394 PMC: 10316079. DOI: 10.5644/ama2006-124.398.


Peptide therapeutics in the management of metastatic cancers.

Bose D, Roy L, Chatterjee S RSC Adv. 2022; 12(33):21353-21373.

PMID: 35975072 PMC: 9345020. DOI: 10.1039/d2ra02062a.